Amgen’s history of clinical trial activity in Australia dates back over 35 years and the country’s reputation for quality and safety continues to make Australia one of the most trusted destinations in the world for Amgen research.
In 2021, Amgen Australia participated in over 40% of Amgen’s active interventional studies globally, contributing more than 1.5% of all interventional enrolled subjects.
In total, 632 Australian patients participated in 51 clinical trials and over 20 investigator sponsored studies, at more than 60 leading Australian hospitals in 2021.
Significantly, Australia is a particularly sought-after location for Amgen’s early development studies. Amgen Australia participated in 52% of Amgen’s global early development studies in 2021, more than anywhere outside the United States.
27 of the 51 clinical trials conducted locally in 2021 were early development studies and 18 of these were first-in-human trials. Australian clinicians are also regularly chosen to dose the first patients in the world.
